The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus



      Cardiovascular complications account for over 50% of mortality among patients with type 2 diabetes mellitus. We quantify the cardiovascular benefit of lowering cholesterol, blood pressure, and glucose levels in these patients.


      We conducted a meta-analysis of randomized controlled trials in type 2 diabetes or diabetes subgroups, comparing the cardiovascular effects of intensive medication control of risk factor levels in standard therapy or placebo. We identified trials by searching MEDLINE (1966 to 2000) and review articles. Treatment details, patient characteristics, and outcome events were obtained using a specified protocol. Data were pooled using fixed-effects models.


      Seven serum cholesterol-lowering trials, six blood pressure–lowering trials, and five blood glucose-lowering trials met eligibility criteria. For aggregate cardiac events (coronary heart disease death and nonfatal myocardial infarction), cholesterol lowering [rate ratio (RR) = 0.75; 95% confidence interval (CI): 0.61 to 0.93) and blood pressure lowering (RR = 0.73; 95% CI: 0.57 to 0.94) produced large, significant effects, whereas intensive glucose lowering reduced events without reaching statistical significance (RR = 0.87; 95% CI: 0.74 to 1.01). We observed this pattern for all individual cardiovascular outcomes. For cholesterol-lowering and blood pressure–lowering therapy, 69 to 300 person-years of treatment were needed to prevent one cardiovascular event.


      The evidence from these clinical trials demonstrates that lipid and blood pressure lowering in patients with type 2 diabetes is associated with substantial cardiovascular benefits. Intensive glucose lowering is essential for the prevention of microvascular disease, but improvements in cholesterol and blood pressure levels are central to reducing cardiovascular disease in these patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Nathan D.M
        • Meigs J
        • Singer D.E
        The epidemiology of cardiovascular disease in type 2 diabetes mellitus.
        Lancet. 1997; 350: SI4-SI9
        • Kuller L.H
        Stroke, and Diabetes.
        in: Harris M.I Diabetes in America. 2nd ed. National Institutes of Health, Bethesda1995: 449-456
        • Morrish N.J
        • Stevens L.K
        • Head J
        • et al.
        A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics) I.
        Diabetologia. 1990; 33: 538-541
        • Moss S.E
        • Klein R
        • Klein B.E.K
        Cause-specific mortality in a population-based study of diabetes.
        Am J Public Health. 1991; 81: 1158-1162
        • Goldberg R.B
        • Mellies M.J
        • Sacks F.M
        • et al.
        Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels.
        Circulation. 1998; 98: 2513-2519
        • UK Prospective Diabetes Study Group
        Tight blood pressure control and risk of cardiovascular and microvascular complications in type 2 diabetes: UKPDS 38.
        BMJ. 1998; 317: 703-713
        • UK Prospective Diabetes Study Group
        Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes: UKPDS 33.
        Lancet. 1998; 352: 837-853
        • Coutinho M
        • Gerstein H.C
        • Wang Y.C
        • Yusuf S
        The relationship between glucose and incident cardiovascular events.
        Diabetes Care. 1999; 22: 233-240
        • Stratton I.M
        • Adler A.I
        • Neil A.W
        • et al.
        Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35).
        BMJ. 2000; 321: 405-412
        • American Diabetes Association
        Detection and management of lipid disorders in diabetes (consensus statement).
        Diabetes Care. 1993; 16: 828-834
        • National Cholesterol Education Program (NCEP) Expert Panel
        Summary of the third report of the NCEP expert panel on detection evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III).
        JAMA. 2001; 285: 2486-2497
      1. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.
        Arch Intern Med. 1997; 157: 2413-2446
        • Meigs J.B
        • Stafford R.S
        Cardiovascular disease prevention practices by U.S. physicians for patients with diabetes.
        J Gen Intern Med. 2000; 15: 220-228
        • Savage P.J
        Cardiovascular complications of diabetes mellitus.
        Ann Intern Med. 1996; 124: 123-126
        • Fagan T.C
        • Sowers J
        Type 2 diabetes mellitus.
        Arch Intern Med. 1999; 159: 1033-1034
        • DeFronzo R.A
        Pharmacologic therapy for type 2 diabetes mellitus.
        Ann Intern Med. 1999; 131: 281-303
        • Boyne M.S
        • Saudek C.D
        Effect of insulin therapy on cardiovascular risk factors in type 2 diabetes.
        Diabetes Care. 1999; 22: 45-53
        • Lebovitz H.E
        Effects of oral antihyperglycemic agents in modifying cardiovascular risk factors in type 2 diabetes.
        Diabetes Care. 1999; 22: 41-44
        • Garber A.J
        Vascular disease and lipids in diabetes.
        Med Clin North Am. 1998; 82: 931-948
        • Ruilope L.M
        • Garcia-Robles R
        How far should blood pressure be reduced in diabetic hypertensive patients?.
        J Hypertens. 1997; 15: S63-S65
        • Koskinen P
        • Manttari M
        • Manninen V
        • et al.
        Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study.
        Diabetes Care. 1992; 15: 820-825
        • Downs J.R
        • Clearfield M
        • Weis D
        • et al.
        Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels.
        JAMA. 1998; 279: 1615-1622
        • Pyorala K
        • Pedersen T.R
        • Kjekshus J
        • et al.
        Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease.
        Diabetes Care. 1997; 20: 614-620
        • The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group
        Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
        N Engl J Med. 1998; 339: 1349-1357
        • Hoogwerf B.J
        • Waness A
        • Cressman M
        • et al.
        Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes. The Post Coronary Artery Bypass Graft Trial.
        Diabetes. 1999; 48: 1289-1294
        • Rubins H.B
        • Robins S.J
        • Collins D
        • et al.
        Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.
        N Engl J Med. 1999; 341: 410-418
        • The Hypertension Detection, and Follow-up Program Cooperative Research Group
        Mortality findings for stepped-care and referred-care participants in the Hypertension Detection and Follow-up Program stratified by other risk factors.
        Prev Med. 1985; 14: 312-335
        • Curb J.D
        • Pressel S.L
        • Cutler J.A
        • et al.
        Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group.
        JAMA. 1996; 276: 1886-1892
        • Hansson L
        • Zanchetti A
        • Carruthers S.G
        • et al.
        Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension.
        Lancet. 1998; 351: 1755-1762
        • Tuomilehto J
        • Rastenyte D
        • Birkenhager W.H
        • et al.
        Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension.
        N Engl J Med. 1999; 340: 677-684
        • Heart Outcomes Prevention Evaluation Study Investigators
        Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.
        Lancet. 2000; 355: 253-259
        • Knatterud G.L
        • Klimt C.R
        • Goldner M.G
        • et al.
        Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes.
        Diabetes. 1982; 21: S1-S81
        • Abraira C
        • Colwell J
        • Nuttall F
        • et al.
        Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes.
        Arch Intern Med. 1997; 157: 181-188
        • Shichiri M
        • Ohkubo Y
        • Wake N
        Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients..
        Diabetes Care. 2000; 23: B21-B29
        • Malmberg K
        • Ryden L
        • Efendic S
        • et al.
        Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study).
        J Am Coll Cardiol. 1995; 26: 57-65
        • Shepherd J
        • Cobbe S.M
        • Ford I
        • et al.
        Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.
        N Engl J Med. 1995; 333: 1301-1307
        • Tatti P
        • Pahor M
        • Byington R.P
        • et al.
        Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM.
        Diabetes Care. 1998; 21: 597-603
        • UK Prospective Diabetes Study Group
        Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39.
        BMJ. 1998; 317: 713-720
        • Hansson L
        • Lindholm L.H
        • Niskanen L
        • et al.
        Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension.
        Lancet. 1999; 353: 611-616
        • Estacio R.O
        • Jeffers B.W
        • Hiatt W.R
        • et al.
        The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension.
        N Engl J Med. 1998; 338: 645-652
        • Laupacis A
        • Sackett D.L
        • Robert R.S
        An assessment of clinically useful measures of the consequences of treatment.
        N Engl J Med. 1988; 318: 1728-1733
        • Ioannidis J.P.A
        • Cappelleri J.C
        • Lau J
        • et al.
        Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness.
        Ann Intern Med. 1995; 122: 856-866
        • Petiti D.B
        Statistical methods in meta-analysis.
        in: Petiti D.B Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. Oxford University Press, New York2000: 94-118
        • Thompson S.G
        Why sources of heterogeneity in meta-analysis should be investigated.
        BMJ. 1994; 309: 1351-1355
      2. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes: I. Design, methods, and baseline characteristics. Diabetes. 1970;19(suppl 2):747–783.

        • Weinstein M.C
        • Siegel J.E
        • Gold M.R
        • et al.
        Recommendations of the panel on cost-effectiveness in health and medicine.
        JAMA. 1996; 276: 1253-1258
        • Adler A.I
        • Stratton I.M
        • Neil A.W
        • et al.
        Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36).
        BMJ. 2000; 321: 412-419
        • Fonseca V
        • Rosenstock J
        • Patwardhan R
        • Salzman A
        Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus.
        JAMA. 2000; 283: 1695-1702
        • Harris M.I
        in: Harris M.I Diabetes in America. 2nd ed. National Institutes of Health, Bethesda1995: 1-13
      3. Action to control cardiovascular risk in diabetes ACCORD. Available at: Accessed July 9, 2001